Bharti Airtel has selected Ericsson Core to support its fixed wireless access services, according to industry sources. In the pharmaceutical sector, Lupin Ltd. has entered into a license and supply agreement with European company Zentiva for the global commercialization of Lupin's biosimilar Certolizumab Pegol. The agreement includes joint investments in the development of the biosimilar, with Lupin receiving an initial payment of $10 million upon execution and a total deal value reported at $50 million. Lupin will be responsible for the development, manufacturing, and supply of the biosimilar. Additionally, HCL Technologies has formed a partnership with Astemo Cypremos to collaborate on the development of autonomous and smart vehicle ecosystems.